Literature DB >> 14558675

Falsely low serum prolactin in two cases of invasive macroprolactinoma.

Christof Schöfl1, Beate Schöfl-Siegert, Johann Hinrich Karstens, Michael Bremer, Thomas Lenarz, Jose Sebastian Fernandez Cuarezma, Madjid Samii, Alexander von zur Mühlen, Georg Brabant.   

Abstract

The differential diagnosis of tumors at the base of the skull comprises meningiomas, neurinomas, gliomas, metastatic carcinomas, chordomas, epidermoids, and pituitary adenomas. About half of the pituitary adenomas are prolactinomas which are unique in a sense that medical therapy causes rapid tumor shrinkage and symptomatic improvement. We report on two patients in which the diagnosis of an invasive macroprolactinoma was masked by apparently low prolactin levels caused by a high-dose hook effect in the chemiluminometric assay. The first case a 49 year old male with impairment of hearing on the left side was presented in the Department of Otorhinolaryngology. A massive invasively growing tumor was demonstrated on a cranial MRI. Endocrine tests revealed normal pituitary function and normoprolactinemia. The patient underwent debulking surgery, occipitocervical fusion because of destruction of the first cervical vertebra and subsequent irradiation. The histopathological diagnosis was invasive prolactinoma. A repeat prolactin (PRL) sample, which was assayed using serial dilutions, revealed a real PRL level of 89,700 ng/ml. Dopamine agonist therapy was initiated under which PRL levels declined in parallel with tumor size. The second case a 40 year old male was presented with acute visual loss. Cranial MRI showed a large tumor at the base of the skull. Based on a transnasal biopsy, the preliminary diagnosis was a poorly differentiated carcinoma for which emergency irradiation was performed. Endocrine tests demonstrated partial hypopituitarism and moderate hyperprolactinemia. Hydrocortisone was substituted and dopamine agonist therapy was started because of moderate hyperprolactinemia. The final histopathological diagnosis was invasive prolactinoma. A repeat PRL sample assayed in serial dilution demonstrated an apparent rise in PRL with a maximum value of 6,460 ng/ml. Under dopamine agonist therapy, PRL declined to normal values, tumor size decreased and cranial nerve palsies disappeared. The apparently falsely low prolactin levels in the initial work-up of both patients were caused by a high-dose hook effect in the PRL assay. Serial dilutions of serum PRL samples is, therefore, mandatory in the diagnostic work-up of patients with large invasive tumors at the base of the skull. This avoids unnecessary aggressive and dangerous treatment like surgery or radiotherapy in cases where pharmacological treatment may be the choice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14558675     DOI: 10.1023/a:1025334001748

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  10 in total

Review 1.  Management of prolactinomas.

Authors:  D Cunnah; M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1991-03       Impact factor: 3.478

Review 2.  Surgical management of pituitary tumors.

Authors:  C B Wilson
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

3.  High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.

Authors:  E St-Jean; F Blain; R Comtois
Journal:  Clin Endocrinol (Oxf)       Date:  1996-03       Impact factor: 3.478

4.  Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report.

Authors:  A L Barkan; W F Chandler
Journal:  Neurosurgery       Date:  1998-04       Impact factor: 4.654

5.  Pituitary apoplexy revisited.

Authors:  M Ahmed; M al-Jurf
Journal:  Arch Intern Med       Date:  1993-09-27

6.  Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.

Authors:  J Verhelst; R Abs; D Maiter; A van den Bruel; M Vandeweghe; B Velkeniers; J Mockel; G Lamberigts; P Petrossians; P Coremans; C Mahler; A Stevenaert; J Verlooy; C Raftopoulos; A Beckers
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

7.  The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas.

Authors:  B M Arafah; D Prunty; J Ybarra; M L Hlavin; W R Selman
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

8.  Pituitary carcinoma: a clinicopathologic study of 15 cases.

Authors:  P J Pernicone; B W Scheithauer; T J Sebo; K T Kovacs; E Horvath; W F Young; R V Lloyd; D H Davis; B L Guthrie; W C Schoene
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

9.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

10.  Low doses of dopamine agonists in the long-term treatment of macroprolactinomas.

Authors:  A Liuzzi; D Dallabonzana; G Oppizzi; G G Verde; R Cozzi; P Chiodini; G Luccarelli
Journal:  N Engl J Med       Date:  1985-09-12       Impact factor: 91.245

  10 in total
  8 in total

Review 1.  Biochemical diagnosis in prolactinomas: some caveats.

Authors:  Stephan Petersenn
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

2.  Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies.

Authors:  Felice Esposito; Daniel F Kelly; Harry V Vinters; Antonio A F DeSalles; Joel Sercarz; Alessandra A Gorgulhos
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

3.  Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'.

Authors:  Maria Fleseriu; Michael Lee; Maria M Pineyro; Mario Skugor; Sethu K Reddy; Elias S Siraj; Amir H Hamrahian
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

4.  Prolactin immunoassay: does the high-dose hook effect still exist?

Authors:  Véronique Raverot; Pauline Perrin; Philippe Chanson; Emmanuel Jouanneau; Thierry Brue; Gérald Raverot
Journal:  Pituitary       Date:  2022-07-06       Impact factor: 3.599

5.  Hyperprolactinemia with normal serum prolactin: "Hook effect" a concern in laboratory medicine aspect.

Authors:  Viroj Wiwanitkit
Journal:  J Hum Reprod Sci       Date:  2010-09

Review 6.  Endocrine Glands and Hearing: Auditory Manifestations of Various Endocrine and Metabolic Conditions.

Authors:  Kripa Elizabeth Cherian; Nitin Kapoor; Suma Susan Mathews; Thomas Vizhalil Paul
Journal:  Indian J Endocrinol Metab       Date:  2017 May-Jun

7.  Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery.

Authors:  Yan-Long Han; Dong-Ming Chen; Cheng Zhang; Miao Pan; Xiao-Peng Yang; Yong-Gang Wu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

8.  Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas.

Authors:  Nicholas A Tritos; Pouneh K Fazeli; Ann McCormack; Susana M Mallea-Gil; Maria M Pineyro; Mirjam Christ-Crain; Stefano Frara; Artak Labadzhyan; Adriana G Ioachimescu; Ilan Shimon; Yutaka Takahashi; Mark Gurnell; Maria Fleseriu
Journal:  Pituitary       Date:  2021-07-20       Impact factor: 4.107

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.